Other languages DiaMedica Therapeutics Inc.

Equities

DMAC

CA25253X2077

Market Closed - Nasdaq Other stock markets 01:30:00 14/05/2024 am IST			5-day change	1st Jan Change
3.19 ^USD	+2.24%		-8.86%	+12.32%

09/05	Transcript : DiaMedica Therapeutics Inc., Q1 2024 Earnings Call, May 09, 2024
17/04	DiaMedica Therapeutics Launches Late-Stage Trial of Potential Stroke Treatment	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

DiaMedica Therapeutics Inc. Announces First Patient Dosed in Relaunch of Its Pivotal Phase /3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic Stroke	18/04
DiaMedica Therapeutics Inc. Announces Executive Changes	11/04
DiaMedica Therapeutics Files $100 Million Mixed Shelf	22/03
DiaMedica Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	20/03
DiaMedica Therapeutics Names Lorianne Masuoka as Chief Medical Officer	23/01
DiaMedica Therapeutics Inc. Appoints Dr. Lorianne Masuoka as Chief Medical Officer	22/01
DiaMedica Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11
Top Premarket Gainers	25/23/25
DiaMedica Therapeutics Inc. Announces the Appointment of Ambarish Shah as Chief Technology Officer	12/23/12
Diamedica Therapeutics Inc. Announces Management Changes	06/23/06
DiaMedica Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	15/23/15
Insider Buy: Diamedica Therapeutics	28/23/28
Insider Buy: Diamedica Therapeutics	27/23/27
Insider Buy: Diamedica Therapeutics	27/23/27
DiaMedica Therapeutics Announces US FDA's Removal of Clinical Hold on Phase 2/3 Trial for Ischemic Stroke Treatment DM199	21/23/21
DiaMedica Therapeutics Inc. Announces That the FDA Has Removed the Clinical Hold on Dm199 Phase 2/3 Trial Forschemic Stroke	21/23/21
Diamedica Therapeutics Announces Appointment of Richard Kuntz to the Board of Directors	30/23/30
Diamedica Therapeutics Inc. Files Complete Clinical Hold Response with the U.S. Food and Drug Administration Regarding the Status of the Remedy2 Study	23/23/23
DiaMedica Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	16/23/16
DiaMedica Therapeutics Appoints Tanya Lewis to its Board of Directors	16/23/16

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages DiaMedica Therapeutics Inc.

Equities

DMAC

CA25253X2077

Other languages

Filters